$PMI

Picard Medical, Inc. (PMI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Executive Officer On October 28, 2026, the Board of Directors (the “Board”) of Picard Medical, Inc., a

Picard Medical exchanged warrants for 200,000 common shares with its placement agent and an employee designee. The warrants were exercisable for 8,187,766 shares before a reverse split. The agreement, effective October 22, 2026, cancels the warrants and their adjustment rights, reducing potential dilution.

Picard Medical, Inc. (PMI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 20, 2026, Picard Medical, Inc. (the “Company”) entered into a Warrant Amendment and Exchange Agreement (the “Exchange Agreement”) with the placement agent (the “Warrant Holder”) of its private placement closed on De

Philip Morris International (PMI) reported Q3 2026 revenue of $11.4B, up from prior year, with EPS down 4.9%. Shipments rose, driven by smoke-free products like IQOS. Combustibles segment showed resilience. PMI raised its quarterly dividend and expects continued growth.

Picard Medical, Inc. (PMI) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On September 30, 2026 (the “Issuance Date”), Picard Medical, Inc. (the “Company”) issued three separate unsecured convertible notes (collectively, the “Not

Picard Medical's stock fell 14.5% in morning trading, reversing recent gains. The company has relied on equity issuances for funding, has a thin cash position, and lacks near-term catalysts. Broader market declines also contributed to the drop. The company is working to meet NYSE listing standards.

Picard Medical Inc. (PMI) shares rose 27% after Q2 2026 revenue of $2.954M beat estimates by 90.58%, up 38.62% YoY. Despite a loss of $(3.05) per share, investors focused on top-line growth and improved gross margins. The company is investing in R&D for its next-gen Emperor Total Artificial Heart, presenting new data at conferences. PMI completed a 1-for-50 reverse stock split in July 2026 to regain NYSE compliance.

Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

Picard Medical, Inc. (PMI) shares rose 40% after reporting Q2 2026 revenue growth of 39% to $3.0M, driven by U.S. sales of SynCardia products. Gross profit improved to $0.6M, and net loss narrowed by 16%. The company also advanced its Emperor Total Artificial Heart platform and completed a reverse stock split to comply with NYSE listing requirements.